Developer docs
API playgroundTry for free, no card

Search company profiles

GPCR Therapeutics

Full company profile

uuid000332p

Namestring
GPCR Therapeutics
Legal namestring
GPCR Therapeutics, Inc.
Websiteurl
gpcr.co.kr
Company typeenum
Private
Founded yearint
2013
Descriptiontext

GPCR Therapeutics is a clinical-stage biopharmaceutical company founded in 2013 in Seoul, South Korea that develops therapeutics targeting G-protein coupled receptor (GPCR) heteromers, with a primary focus on CXCR4 combinations. Its core technology is the proprietary C-Het™ drug discovery platform, which has catalogued over 1,000 GPCR pairs and systematically identified synergistic heteromer mechanisms — most notably CXCR4-B2AR, CXCR4-LPA1, and CXCR4-HRH1 — validated through peer-reviewed publications in PNAS, Blood, Nature Scientific Reports, PLOS ONE, and Cell Communication and Signaling. The lead clinical asset is GPC-100/Burixafor, a small-molecule CXCR4 antagonist being advanced as a combination therapy with propranolol (GPC201) for hematopoietic stem cell mobilization in multiple myeloma patients undergoing autologous stem cell transplantation.

The business is structured around two product layers: a proprietary pipeline built on the C-Het™ platform, and out-licensed or partnered assets. GPC-100/Burixafor progressed through a US Phase 2 trial that reported an 89.7% primary-endpoint success rate, received FDA Orphan Drug Designation in October 2024, and is now being advanced by Exicure, Inc. following its January 2025 acquisition of the US subsidiary. The CXCR4-LPA1 combination for idiopathic pulmonary fibrosis has been out-licensed to Bridge Biotherapeutics under a 50:50 profit-share arrangement, while the CXCR4-HRH1 program remains research-stage. The company has raised approximately KRW 714 billion (cumulative across 6 funding rounds from 20+ institutional investors), passed the KOSDAQ Technology Evaluation with A-BBB grades, and was preparing for a KOSDAQ listing prior to the Exicure transaction.

Monetization is event-driven rather than product-based: revenue consists of licensing upfronts, milestone payments tied to clinical and regulatory progress, and profit-share on partnered commercialization. The company has not disclosed product pricing, has no approved drug, and is pre-revenue in the conventional sense. Its customers and counterparties are research collaborators and pharmaceutical partners — including MD Anderson, Dana-Farber, Memorial Sloan Kettering, Cleveland Clinic, City of Hope, Seoul National University, AdAlta, TaiGen, Bridge Biotherapeutics, and Exicure — rather than payers or end-prescribers.

Short descriptiontext

GPCR Therapeutics is a clinical-stage biopharmaceutical company that develops small-molecule and combination therapies targeting CXCR4 GPCR heteromers for oncology and fibrosis, serving patients via out-licensing, partnerships, and post-acquisition commercialization through Exicure.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSeoul, South Korea
HQ citystring
Seoul
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
GPCR drug discovery, clinical-stage biopharmaceutical, stem cell mobilization, hematological cancer therapeutics, CXCR4 antagonist development
Industry3 codes
PRIMARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAH
Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIALAF
Translational Medicine & Biomarkers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Biological Product (except Diagnostic) Manufacturing325414
  • Scientific Research and Development Services5417
SIC code2 codes
  • Biological Products, (No Disgnostic Substances)2836
  • Pharmaceutical Preparations2834
Product category
Clinical-stage Biopharmaceuticals
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model4 records
1Drug Development Milestones
TypeLicensing Royalties
Description

Revenue from milestone payments as drug candidates progress through clinical development stages under licensing and partnership agreements

gpcr.co.kr
2Technology Licensing
TypeLicensing Royalties
Description

Out-licensing of proprietary GPCR heteromer targeting technology and combination therapy patents for IPF and other indications. Received KRW 2 billion upfront from Bridge Biotherapeutics with 50:50 profit share on future commercialization.

gpcr.co.kr
3Future Product Commercialization
TypeOne Time License
Description

Revenue from commercialization of proprietary drug candidates including GPC-100/Burixafor for stem cell mobilization and combination therapies. Expected to generate first revenue from technology exports from 2025.

gpcr.co.kr
4Acquisition Payment
TypeTransaction Fee
Description

Following January 2025 acquisition by Exicure, Inc., receiving milestone payments including $1 million Phase 2 trial completion payment in January 2026

biospace.com
Marketing channels6 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels3 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeServices
Services
Brand1 of 2 records shown
1C-Het™ Platform
Description

GPCR Therapeutics' proprietary drug discovery platform based on CXCR4 Heteromer Interactome and CXCR4 Heteromer Evaluator for systematic analysis of CXCR4-GPCRx target mechanisms.

gpcr.co.kr
+1 more record
Core offering1 text field

GPCR Therapeutics is a clinical-stage international biopharmaceutical company developing novel therapeutics targeting GPCR (G-protein coupled receptor) heteromers, particularly CXCR4 in combination with other GPCRs. The company's lead asset GPC-100/Burixafor is a CXCR4 antagonist being developed as a combination therapy (GPC201) with propranolol for hematopoietic stem cell mobilization in multiple myeloma patients undergoing autologous stem cell transplantation. The proprietary C-Het drug discovery platform has identified over 1,000 GPCR pairs for therapeutic development across cancer, fibrotic diseases, and stem cell mobilization indications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 5 values shown
  • 89.7% of multiple myeloma patients achieved primary endpoint of successful hematopoietic progenitor cell mobilization within two leukapheresis sessions
+4 more records
Product overview1 text field

GPCR Therapeutics is a clinical-stage biopharmaceutical company developing therapeutics targeting GPCR heteromers in cancer. The company operates its proprietary C-Het drug discovery platform and has a pipeline of combination therapies. Lead product GPC-100/Burixafor is a CXCR4 antagonist being developed as GPC201 (combined with propranolol) for stem cell mobilization in multiple myeloma. The company also has pipeline programs targeting CXCR4-LPA1 for fibrosis (out-licensed to Bridge Biotherapeutics) and CXCR4-HRH1 for solid tumors.

Product and service5 records
1GPC-100 (Burixafor)
CategoryCore Product - Small Molecule Drug
Description

A novel CXCR4 antagonist and potent hematopoietic stem cell mobilizer that disrupts the CXCL12/CXCR4 axis in the bone marrow, releasing hematopoietic stem cells into circulation. It targets CXCR4, one of the most prevalent chemokine GPCRs overexpressed in more than 23 cancers.

2GPC201 (GPC-100 + Propranolol)
CategoryCore Product - Combination Therapy
Description

A combination therapy consisting of GPC-100 (CXCR4 antagonist) and propranolol (FDA-approved ADRB2 inhibitor) for stem cell mobilization in multiple myeloma patients. The combination targets CXCR4 and B2AR GPCR pairs, demonstrating synergistic effects that improve upon standard of care treatments.

3C-Het Drug Discovery Platform
CategoryDrug Discovery Platform
Description

A proprietary drug discovery platform based on CXCR4 Heteromer Interactome data that systematically analyzes and validates mechanisms of action for CXCR4-GPCRx combinations, enabling efficient and continuous development of therapeutic products through licensing and partnership arrangements.

4CXCR4-LPA1 Combination Therapy for IPF
CategoryPipeline Product - Licensed Combination Therapy
Description

A combination therapy targeting CXCR4 and LPA1 receptors for the treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases. Out-licensed to Bridge Biotherapeutics for joint development and commercialization with 50:50 profit share arrangement.

5CXCR4-HRH1 Combination Therapy
CategoryPipeline Product - Research Stage
Description

Research-stage combination therapy targeting CXCR4 and histamine receptor H1 (HRH1) for anticancer therapy, based on findings that co-expression correlates with poor prognosis in breast cancer patients.

Scale indicator9 records

Each record includes

Type, Value, Description, Source

Partnership6 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-01-01
Description

Exicure acquired GPCR Therapeutics USA Inc. in January 2025 to expand its GPCR-targeted therapeutics capabilities. The acquisition brought burixafor (GPC-100) into Exicure's pipeline. Following the acquisition, Exicure achieved a Phase 2 trial milestone triggering a $1 million payment to GPCR Therapeutics in January 2026. GPCR's operations continue under Exicure with focus on stem cell mobilization assets.

2Bridge Biotherapeutics
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2023-12-14
Description

Out-licensing agreement for CXCR4-LPA1 inhibitor combination method for treatment of idiopathic pulmonary fibrosis (IPF). GPCR received upfront payment of KRW 2 billion (~$1.5 million) with 50:50 profit-share on future commercialization including sub-licenses. Collaboration leverages Bridge's BBT-877 autotaxin inhibitor for IPF combined with GPCR's CXCR4 targeting technology.

gpcr.co.kr
3TaiGen Biotechnology Co. Ltd.
Strategic tierSecondaryTypeStrategic or Co-development PartnerAnnounced on2023-08-01
Description

Collaboration on clinical development of GPC-100 (burixafor) for stem cell mobilization. Joint publication in Clinical Pharmacology in Drug Development demonstrating safety, PK/PD profile, and 3-14 fold increase in CD34+ cells in healthy subjects.

gpcr.co.kr
Strategic tierSecondaryTypeStrategic or Co-development PartnerAnnounced on2023-02-01
Description

Joint research collaboration with Dr. Pamela Becker on acute myeloid leukemia (AML) treatment strategy targeting CXCR4 and ADRB2 simultaneously. Analysis of 124 AML patient samples showing CXCR4 overexpression correlation. Results presented at AACR 2024.

Strategic tierSecondaryTypeStrategic or Co-development PartnerAnnounced on2022-10-13
Description

Collaboration to evaluate AdAlta's CXCR4 inhibiting i-bodies combined with beta blockers from GPCR's platform for novel cancer therapeutics. AdAlta supplies panel of CXCR4 inhibiting i-bodies; GPCR evaluates in combination with B2AR inhibitors for in vitro and in vivo studies. AdAlta has first option to license resulting products for treating cancer.

6Seoul National University
Strategic tierSecondaryTypeStrategic or Co-development PartnerAnnounced on2020-01-01
Description

Academic collaboration with Professor Won-Ki Huh's laboratory for research on GPCR heteromers including CXCR4-B2AR, CXCR4-HRH1, and CXCR4-LPA1 interactions. Multiple joint publications in Nature Scientific Reports, PLOS ONE, Cell Communication and Signaling, and PNAS.

gpcr.co.kr
Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers8 records
TypeDirect peer
Description

Direct competitor in CXCR4 antagonism and stem cell mobilization. BioLineRx's motixafortide (Aphexda) is FDA-approved in combination with G-CSF for autologous stem cell transplantation in multiple myeloma, representing the most direct commercial benchmark to GPCR's GPC-100/burixafor program.

TypeDirect peer
Description

CXCR4 antagonist developer with FDA-approved mavorixafor (Xolremdi) for WHIM syndrome. X4 targets overlapping CXCR4 biology with a focus on rare immunology indications, making it directly comparable in mechanism of action and target validation.

TypeEmerging player
Description

Australian biotech developing CXCR4-targeting i-bodies for cancer and fibrosis. AdAlta is an active collaboration partner of GPCR, evaluating i-body + beta-blocker combinations, making it both a peer and partner in the CXCR4 modality space.

4Sosei Heptares
TypeBroad incumbent
Description

Major GPCR-focused biopharmaceutical company with proprietary StaR platform and multiple clinical-stage GPCR-targeted programs. Sosei Heptares represents the largest and most established commercial player in GPCR drug discovery, comparable in underlying science focus though broader in scope.

TypeEmerging player
Description

Stem cell mobilization and gene therapy preparation company developing MGTA-456 and related mobilization programs. Although focused on different mobilization approaches, Magenta operates in the same target indication (stem cell mobilization for transplant/gene therapy) as GPCR.

6Bridge Biotherapeutics
TypeEmerging player
Description

Korean clinical-stage biotech developing BBT-877 (autotaxin inhibitor) for IPF. Bridge Biotherapeutics is the licensee of GPCR's CXCR4-LPA1 combination for IPF, making it both a partner and a comparable Korean-listed clinical-stage biotech with respiratory/fibrosis focus.

TypeBroad incumbent
Description

Clinical-stage biotechnology company that acquired GPCR Therapeutics USA Inc. in January 2025. Now the developer and commercializer of burixafor in the US, Exicure is both the acquirer and a strategic peer operating in the same GPCR-targeted therapeutic space.

TypeEmerging player
Description

Clinical-stage GPCR-focused biopharmaceutical company developing oral small molecules for metabolic and cardiopulmonary diseases. While focused on different indications, Structure Therapeutics represents a comparable next-generation GPCR drug discovery platform with similar business model and development stage.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers7 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment5 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles8 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

Subsidiaries1 record

Each record includes

Name, Acquired on, Relationship type, Type, Business focus

Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds4 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

GPCR Therapeutics

Clinical-stage Biopharmaceuticalsgpcr.co.kr

GPCR Therapeutics is a clinical-stage biopharmaceutical company that develops small-molecule and combination therapies targeting CXCR4 GPCR heteromers for oncology and fibrosis, serving patients via out-licensing, partnerships, and post-acquisition commercialization through Exicure.

What GPCR Therapeutics does

GPCR Therapeutics is a clinical-stage biopharmaceutical company founded in 2013 in Seoul, South Korea that develops therapeutics targeting G-protein coupled receptor (GPCR) heteromers, with a primary focus on CXCR4 combinations. Its core technology is the proprietary C-Het™ drug discovery platform, which has catalogued over 1,000 GPCR pairs and systematically identified synergistic heteromer mechanisms — most notably CXCR4-B2AR, CXCR4-LPA1, and CXCR4-HRH1 — validated through peer-reviewed publications in PNAS, Blood, Nature Scientific Reports, PLOS ONE, and Cell Communication and Signaling. The lead clinical asset is GPC-100/Burixafor, a small-molecule CXCR4 antagonist being advanced as a combination therapy with propranolol (GPC201) for hematopoietic stem cell mobilization in multiple myeloma patients undergoing autologous stem cell transplantation.

The business is structured around two product layers: a proprietary pipeline built on the C-Het™ platform, and out-licensed or partnered assets. GPC-100/Burixafor progressed through a US Phase 2 trial that reported an 89.7% primary-endpoint success rate, received FDA Orphan Drug Designation in October 2024, and is now being advanced by Exicure, Inc. following its January 2025 acquisition of the US subsidiary. The CXCR4-LPA1 combination for idiopathic pulmonary fibrosis has been out-licensed to Bridge Biotherapeutics under a 50:50 profit-share arrangement, while the CXCR4-HRH1 program remains research-stage. The company has raised approximately KRW 714 billion (cumulative across 6 funding rounds from 20+ institutional investors), passed the KOSDAQ Technology Evaluation with A-BBB grades, and was preparing for a KOSDAQ listing prior to the Exicure transaction.

Monetization is event-driven rather than product-based: revenue consists of licensing upfronts, milestone payments tied to clinical and regulatory progress, and profit-share on partnered commercialization. The company has not disclosed product pricing, has no approved drug, and is pre-revenue in the conventional sense. Its customers and counterparties are research collaborators and pharmaceutical partners — including MD Anderson, Dana-Farber, Memorial Sloan Kettering, Cleveland Clinic, City of Hope, Seoul National University, AdAlta, TaiGen, Bridge Biotherapeutics, and Exicure — rather than payers or end-prescribers.

GPCR Therapeutics firmographics

Firmographics
Name
GPCR Therapeutics
Legal name
GPCR Therapeutics, Inc.
Website
https://gpcr.co.kr
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
11–50 employees
Short description
GPCR Therapeutics is a clinical-stage biopharmaceutical company that develops small-molecule and combination therapies targeting CXCR4 GPCR heteromers for oncology and fibrosis, serving patients via out-licensing, partnerships, and post-acquisition commercialization through Exicure.
Ownership category
akta.pro rank

GPCR Therapeutics industry classification

Industry
Product category
Clinical-stage Biopharmaceuticals
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Biological Product (except Diagnostic) Manufacturing (325414), Scientific Research and Development Services (5417)
SIC
Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAH
Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAIALAF
Translational Medicine & Biomarkers
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development

Keywords

  • GPCR drug discovery
  • Clinical-stage biopharmaceutical
  • Stem cell mobilization
  • Hematological cancer therapeutics
  • CXCR4 antagonist development

Where GPCR Therapeutics is headquartered

Location

Headquarters

HQ city
Seoul
HQ country
South Korea
HQ region
Asia

Offices2 records

Markets served

GPCR Therapeutics business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Drug Development Milestones: Revenue from milestone payments as drug candidates progress through clinical development stages under licensing and partnership agreements
  2. Technology Licensing: Out-licensing of proprietary GPCR heteromer targeting technology and combination therapy patents for IPF and other indications. Received KRW 2 billion upfront from Bridge Biotherapeutics with 50:50 profit share on future commercialization.
  3. Future Product Commercialization: Revenue from commercialization of proprietary drug candidates including GPC-100/Burixafor for stem cell mobilization and combination therapies. Expected to generate first revenue from technology exports from 2025.
  4. Acquisition Payment: Following January 2025 acquisition by Exicure, Inc., receiving milestone payments including $1 million Phase 2 trial completion payment in January 2026

Go-to-market motion2 records

Distribution channels3 records

Marketing channels6 records

GPCR Therapeutics product offering

Product offering

Core offering

GPCR Therapeutics is a clinical-stage international biopharmaceutical company developing novel therapeutics targeting GPCR (G-protein coupled receptor) heteromers, particularly CXCR4 in combination with other GPCRs. The company's lead asset GPC-100/Burixafor is a CXCR4 antagonist being developed as a combination therapy (GPC201) with propranolol for hematopoietic stem cell mobilization in multiple myeloma patients undergoing autologous stem cell transplantation. The proprietary C-Het drug discovery platform has identified over 1,000 GPCR pairs for therapeutic development across cancer, fibrotic diseases, and stem cell mobilization indications.

Product overview

GPCR Therapeutics is a clinical-stage biopharmaceutical company developing therapeutics targeting GPCR heteromers in cancer. The company operates its proprietary C-Het drug discovery platform and has a pipeline of combination therapies. Lead product GPC-100/Burixafor is a CXCR4 antagonist being developed as GPC201 (combined with propranolol) for stem cell mobilization in multiple myeloma. The company also has pipeline programs targeting CXCR4-LPA1 for fibrosis (out-licensed to Bridge Biotherapeutics) and CXCR4-HRH1 for solid tumors.

Differentiator

Problem solved

Functional benefit

Brands

  • C-Het™ Platform: GPCR Therapeutics' proprietary drug discovery platform based on CXCR4 Heteromer Interactome and CXCR4 Heteromer Evaluator for systematic analysis of CXCR4-GPCRx target mechanisms.
  • GPC-100 + Propranolol (GPC201)

Products and services

  • GPC-100 (Burixafor) A novel CXCR4 antagonist and potent hematopoietic stem cell mobilizer that disrupts the CXCL12/CXCR4 axis in the bone marrow, releasing hematopoietic stem cells into circulation. It targets CXCR4, one of the most prevalent chemokine GPCRs overexpressed in more than 23 cancers.
  • GPC201 (GPC-100 + Propranolol) A combination therapy consisting of GPC-100 (CXCR4 antagonist) and propranolol (FDA-approved ADRB2 inhibitor) for stem cell mobilization in multiple myeloma patients. The combination targets CXCR4 and B2AR GPCR pairs, demonstrating synergistic effects that improve upon standard of care treatments.
  • C-Het Drug Discovery Platform A proprietary drug discovery platform based on CXCR4 Heteromer Interactome data that systematically analyzes and validates mechanisms of action for CXCR4-GPCRx combinations, enabling efficient and continuous development of therapeutic products through licensing and partnership arrangements.
  • CXCR4-LPA1 Combination Therapy for IPF A combination therapy targeting CXCR4 and LPA1 receptors for the treatment of idiopathic pulmonary fibrosis (IPF) and other fibrotic diseases. Out-licensed to Bridge Biotherapeutics for joint development and commercialization with 50:50 profit share arrangement.
  • CXCR4-HRH1 Combination Therapy Research-stage combination therapy targeting CXCR4 and histamine receptor H1 (HRH1) for anticancer therapy, based on findings that co-expression correlates with poor prognosis in breast cancer patients.

Quantifiable outcome

  • 89.7% of multiple myeloma patients achieved primary endpoint of successful hematopoietic progenitor cell mobilization within two leukapheresis sessions
  • +4 more outcomes

Companies that use GPCR Therapeutics

Customer profile

Named customers7 records

Segments5 records

Ideal customer profiles2 records

GPCR Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

GPCR Therapeutics partnerships and signals

Strategic signal

Partnerships

Six partnerships are on record, tiered core and secondary.

  • Exicure, Inc.coreStrategic or Co-development Partner · 1 January 2025Exicure acquired GPCR Therapeutics USA Inc. in January 2025 to expand its GPCR-targeted therapeutics capabilities. The acquisition brought burixafor (GPC-100) into Exicure's pipeline. Following the acquisition, Exicure achieved a Phase 2 trial milestone triggering a $1 million payment to GPCR Therapeutics in January 2026. GPCR's operations continue under Exicure with focus on stem cell mobilization assets.
  • Bridge BiotherapeuticscoreStrategic or Co-development Partner · 14 December 2023Out-licensing agreement for CXCR4-LPA1 inhibitor combination method for treatment of idiopathic pulmonary fibrosis (IPF). GPCR received upfront payment of KRW 2 billion (~$1.5 million) with 50:50 profit-share on future commercialization including sub-licenses. Collaboration leverages Bridge's BBT-877 autotaxin inhibitor for IPF combined with GPCR's CXCR4 targeting technology.
  • TaiGen Biotechnology Co. Ltd.secondaryStrategic or Co-development Partner · 1 August 2023Collaboration on clinical development of GPC-100 (burixafor) for stem cell mobilization. Joint publication in Clinical Pharmacology in Drug Development demonstrating safety, PK/PD profile, and 3-14 fold increase in CD34+ cells in healthy subjects.
  • City of Hope National Medical CentersecondaryStrategic or Co-development Partner · 1 February 2023Joint research collaboration with Dr. Pamela Becker on acute myeloid leukemia (AML) treatment strategy targeting CXCR4 and ADRB2 simultaneously. Analysis of 124 AML patient samples showing CXCR4 overexpression correlation. Results presented at AACR 2024.
  • AdAlta LimitedsecondaryStrategic or Co-development Partner · 13 October 2022Collaboration to evaluate AdAlta's CXCR4 inhibiting i-bodies combined with beta blockers from GPCR's platform for novel cancer therapeutics. AdAlta supplies panel of CXCR4 inhibiting i-bodies; GPCR evaluates in combination with B2AR inhibitors for in vitro and in vivo studies. AdAlta has first option to license resulting products for treating cancer.
  • Seoul National UniversitysecondaryStrategic or Co-development Partner · 1 January 2020Academic collaboration with Professor Won-Ki Huh's laboratory for research on GPCR heteromers including CXCR4-B2AR, CXCR4-HRH1, and CXCR4-LPA1 interactions. Multiple joint publications in Nature Scientific Reports, PLOS ONE, Cell Communication and Signaling, and PNAS.

Scale indicators9 records

Recent moves5 records

Expansion highlights6 records

GPCR Therapeutics competitors and assessment

Company assessment

Direct peers

  • BioLineRx: Direct competitor in CXCR4 antagonism and stem cell mobilization. BioLineRx's motixafortide (Aphexda) is FDA-approved in combination with G-CSF for autologous stem cell transplantation in multiple myeloma, representing the most direct commercial benchmark to GPCR's GPC-100/burixafor program.
  • X4 Pharmaceuticals: CXCR4 antagonist developer with FDA-approved mavorixafor (Xolremdi) for WHIM syndrome. X4 targets overlapping CXCR4 biology with a focus on rare immunology indications, making it directly comparable in mechanism of action and target validation.

Emerging players

  • AdAlta Limited: Australian biotech developing CXCR4-targeting i-bodies for cancer and fibrosis. AdAlta is an active collaboration partner of GPCR, evaluating i-body + beta-blocker combinations, making it both a peer and partner in the CXCR4 modality space.
  • Magenta Therapeutics: Stem cell mobilization and gene therapy preparation company developing MGTA-456 and related mobilization programs. Although focused on different mobilization approaches, Magenta operates in the same target indication (stem cell mobilization for transplant/gene therapy) as GPCR.
  • Bridge Biotherapeutics: Korean clinical-stage biotech developing BBT-877 (autotaxin inhibitor) for IPF. Bridge Biotherapeutics is the licensee of GPCR's CXCR4-LPA1 combination for IPF, making it both a partner and a comparable Korean-listed clinical-stage biotech with respiratory/fibrosis focus.
  • Structure Therapeutics: Clinical-stage GPCR-focused biopharmaceutical company developing oral small molecules for metabolic and cardiopulmonary diseases. While focused on different indications, Structure Therapeutics represents a comparable next-generation GPCR drug discovery platform with similar business model and development stage.

Broad incumbents

  • Sosei Heptares: Major GPCR-focused biopharmaceutical company with proprietary StaR platform and multiple clinical-stage GPCR-targeted programs. Sosei Heptares represents the largest and most established commercial player in GPCR drug discovery, comparable in underlying science focus though broader in scope.
  • Exicure: Clinical-stage biotechnology company that acquired GPCR Therapeutics USA Inc. in January 2025. Now the developer and commercializer of burixafor in the US, Exicure is both the acquirer and a strategic peer operating in the same GPCR-targeted therapeutic space.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

GPCR Therapeutics social profiles

Digital presence

GPCR Therapeutics compliance and trust

Trust signal

Compliance1 record

GPCR Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

GPCR Therapeutics leadership team

Management profile

Number of profiles

Profiles8 records

GPCR Therapeutics subsidiaries and ownership

Company hierarchy

Subsidiaries1 record

GPCR Therapeutics funding detail

Funding detail

Funding overview

Funding rounds4 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

GPCR Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about GPCR Therapeutics

What does GPCR Therapeutics do?

GPCR Therapeutics is a clinical-stage international biopharmaceutical company developing novel therapeutics targeting GPCR (G-protein coupled receptor) heteromers, particularly CXCR4 in combination with other GPCRs. The company's lead asset GPC-100/Burixafor is a CXCR4 antagonist being developed as a combination therapy (GPC201) with propranolol for hematopoietic stem cell mobilization in multiple myeloma patients undergoing autologous stem cell transplantation. The proprietary C-Het drug discovery platform has identified over 1,000 GPCR pairs for therapeutic development across cancer, fibrotic diseases, and stem cell mobilization indications.

Is GPCR Therapeutics a public or private company?

GPCR Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was GPCR Therapeutics founded?

GPCR Therapeutics was founded in 2013. It employs 11 to 50 people.

Where is GPCR Therapeutics based?

GPCR Therapeutics is headquartered in Seoul, South Korea, in the Asia region.

How does GPCR Therapeutics make money?

Four revenue lines are on record. Drug Development Milestones are the primary driver. The others are technology Licensing, future Product Commercialization and acquisition Payment.

Who are GPCR Therapeutics's main competitors?

Direct peers on record are BioLineRx and X4 Pharmaceuticals. Emerging players are AdAlta Limited, Magenta Therapeutics, Bridge Biotherapeutics and Structure Therapeutics. Broad incumbents are Sosei Heptares and Exicure.

Does GPCR Therapeutics have an API?

No public API is recorded for GPCR Therapeutics.

What industry is GPCR Therapeutics in?

GPCR Therapeutics's product category is Clinical-stage Biopharmaceuticals. Its primary akta.pro industry code is HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation), with a secondary code of HLAAAIAH, Protein Interaction & Structural Biology Platforms (cryo-EM, X-ray, NMR, biophysics). Its NAICS code is 541714 and its SIC code is 2836.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Quiver QuantitativeExicure Announces Planned Issuance of Common Stock to Settle $1.0 Million Milestone Payment to GPCR Therapeutics | XCUR Stock NewsExicure, Inc. announced plans to issue 172,058 shares of common stock to GPCR Therapeutics, Inc. to settle a $1.0 million clinical milestone payment triggered by the completion of the Phase 2 trial of Burixafor and the submission of the Clinical Study Report to the FDA on January 16, 2026. The shares will be issued at a deemed value of $5.81 per share, with completion expected in August 2026. Exicure stated the issuance will allow the company to preserve cash and maintain financial flexibility as it pursues operational and strategic priorities following its restructuring.YahooExicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity IssuanceExicure, Inc. announced it will issue 172,058 shares of common stock to GPCR Therapeutics, Inc. during August 2026 to settle a $1.0 million clinical milestone payment obligation. The milestone was triggered by completion of the Phase 2 clinical trial of Burixafor (GPC-100), including submission of the Clinical Study Report to the FDA on January 16, 2026. The shares will be issued at $5.81 per share, allowing Exicure to preserve cash and maintain financial flexibility while pursuing operational and strategic priorities.Stock TitanExicure Expects 172K Shares for $1M MilestoneExicure, Inc. announced it will issue 172,058 shares of common stock to GPCR Therapeutics, Inc. during August 2026 to settle a $1.0 million clinical milestone payment triggered by the completion of a Phase 2 clinical trial for Burixafor (GPC-100) and submission of the Clinical Study Report to the FDA on January 16, 2026. The shares will be issued at $5.81 per share. The company stated this equity issuance will preserve cash and maintain financial flexibility as it pursues operational and strategic priorities.GlobeNewswireExicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity IssuanceExicure is set to settle a $1.0 million clinical milestone payment through the issuance of 172,058 shares of common stock to GPCR Therapeutics. The milestone was triggered by the completion of a Phase 2 clinical trial involving Burixafor, and the shares are expected to be issued in August 2026.openPR.comG-Protein Coupled Receptors Market Projected to Grow at 5.4% CAGR Through 2033: Persistence Market ResearchPersistence Market Research projects the global G-Protein Coupled Receptors (GPCR) market will grow from US$ 4.2 billion in 2026 to US$ 6.1 billion by 2033, representing a 5.4% CAGR, driven by GLP-1 receptor agonist success generating nearly US$ 30 billion in annual sales, increasing precision medicine investments, and 35% of FDA-approved medications already targeting GPCRs. North America is expected to hold 39% market share in 2025, while Asia-Pacific emerges as the fastest-growing region with 6.0-7.0% projected CAGR. In January 2025, Exicure, Inc. acquired GPCR Therapeutics USA Inc. to expand its GPCR-targeted therapeutics capabilities.Investing.comExicure completes Phase 2 trial milestone and plans $1 million payment to GPCR Therapeutics By Investing.comExicure announced that it achieved a Phase 2 trial milestone for its stem cell mobilizer, leading to a $1 million payment obligation to GPCR Therapeutics Inc. The milestone was based on successful completion of the trial and submission of a Clinical Study Report to the FDA, with Exicure also reporting positive results from another trial and strategic financial management activities.GlobeNewswireNew Burixafor Clinical Data to be Presented as an Oral Presentation at the 2025 ASH Annual MeetingExicure, Inc. announced that results from its completed Phase 2 study of burixafor, a small molecule CXCR4 antagonist for stem cell mobilization in multiple myeloma patients, will be presented as an oral presentation at the 67th American Society of Hematology Annual Meeting in Orlando, Florida on December 8, 2025. The study demonstrated an excellent safety profile, with 18 out of 19 patients who elected to undergo transplant successfully proceeding to autologous hematopoietic cell transplantation, including patients previously treated with daratumumab. Burixafor (GPC-100) entered Exicure's pipeline following the company's acquisition of GPCR Therapeutics, Inc. in January 2025, and is also being evaluated for sickle cell disease, rare diseases requiring transplant, and as a chemosensitizing agent in acute myeloid leukemia.Business Wire BlogExicure, Inc. Partners with GPCR Therapeutics to Fuel New Growth in BiotechExicure signed an MOU with GPCR Therapeutics to acquire GPCR USA and transfer its CXCR4 inhibitor pipeline, including a Phase 2 trial for multiple myeloma. The company plans $14M in capital investments for the acquisition and clinical costs. It also intends collaborative R&D in immuno-oncology, fibrosis, and obesity.Labiotech.euBeyond Biotech podcast 34: eClinical Solutions, GPCR Therapeutics, Orbsen TherapeuticsThe Beyond Biotech podcast 34 features Katrina Rice from eClinical Solutions, Pina Cardarelli from GPCR Therapeutics, and Larry A Couture from Orbsen Therapeutics. GPCR Therapeutics launched a phase 2 trial for its GPC-100 asset in multiple myeloma, while eClinical Solutions published a survey of 60 biopharma professionals on clinical data challenges.PR NewswirePharmaVentures advises GPCR Therapeutics on their acquisition of BurixaforPharmaVentures acted as advisor to GPCR Therapeutics on its acquisition of Burixafor, a CXCR4-targeting compound being licensed exclusively from TaiGen Biotechnology for worldwide development. The deal positions GPCR Therapeutics, a Korean biotech company specializing in GPCR heteromer science for anti-cancer therapies, to advance Burixafor in the oncology field. PharmaVentures noted that the transaction reflects the growing internationalization of South Korea's innovative biotechnology sector.